Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of both complex mixture generic and novel drugs.
Spotlight
Momenta Pharmaceuticals Announces Positive Results from
M118 EMINENCE Trial
–Data supports feasibility of utilizing M118 as a procedural anticoagulant –
CAMBRIDGE, MA – September 24, 2009 – Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) Phase 2 multicenter trial evaluating intravenous use of M118.
